NEW DELHI: Drug firm Lupin 3.64 % today said it has received an Establishment Inspection Report (EIR) from the US health regulator for its Pithampur, Unit 1 manufacturing facility in Madhya Pradesh. 

The inspection was conducted in July 2017, it said in a BSE filing. 

USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection. 

In November last, Lupin had received warning letter from USFDA (US Food and Drug Administration) for its manufacturing facilities in Goa and Pithampur.